Arrowstreet Capital’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $87.8M | Buy |
578,609
+225,027
| +64% | +$34.1M | 0.06% | 286 |
|
|
2025
Q1 | $53.2M | Buy |
+353,582
| New | +$53.2M | 0.04% | 360 |
|
|
2022
Q1 | – | Sell |
-46,901
| Closed | -$17.7M | – | 1247 |
|
|
2021
Q4 | $17.7M | Sell |
46,901
-1,099
| -2% | -$414K | 0.02% | 514 |
|
|
2021
Q3 | $19.8M | Buy |
+48,000
| New | +$19.8M | 0.02% | 535 |
|
|
2020
Q3 | – | Sell |
-2,800
| Closed | -$488K | – | 2357 |
|
|
2020
Q2 | $488K | Buy |
+2,800
| New | +$488K | ﹤0.01% | 1971 |
|
|
2019
Q4 | – | Sell |
-4,900
| Closed | -$649K | – | 1773 |
|
|
2019
Q3 | $649K | Sell |
4,900
-169,559
| -97% | -$22.5M | ﹤0.01% | 1263 |
|
|
2019
Q2 | $24.8M | Buy |
174,459
+8,325
| +5% | +$1.18M | 0.06% | 320 |
|
|
2019
Q1 | $24.1M | Buy |
166,134
+104,834
| +171% | +$15.2M | 0.06% | 315 |
|
|
2018
Q4 | $6.94M | Buy |
+61,300
| New | +$6.94M | 0.02% | 507 |
|
|
2018
Q3 | – | Sell |
-99,847
| Closed | -$11.2M | – | 1113 |
|
|
2018
Q2 | $11.2M | Sell |
99,847
-93,167
| -48% | -$10.5M | 0.03% | 400 |
|
|
2018
Q1 | $20.6M | Sell |
193,014
-231,466
| -55% | -$24.7M | 0.05% | 312 |
|
|
2017
Q4 | $46.5M | Buy |
424,480
+253,180
| +148% | +$27.7M | 0.11% | 188 |
|
|
2017
Q3 | $18.5M | Buy |
171,300
+167,900
| +4,938% | +$18.1M | 0.05% | 293 |
|
|
2017
Q2 | $344K | Buy |
+3,400
| New | +$344K | ﹤0.01% | 926 |
|
|
2016
Q4 | – | Sell |
-56,600
| Closed | -$4.72M | – | 1803 |
|
|
2016
Q3 | $4.72M | Buy |
+56,600
| New | +$4.72M | 0.02% | 660 |
|